- What's the Analyst Recommendation for Baudax Bio Inc. (BXRX)?
- Let’s Take a Look at Plantronics Inc. (PLT) Stock
- Is it Time to Sell/Buy Isoray Inc. (ISR) Stock After Recent Trade?
- Avis Budget Group Inc. (CAR) is up 12.41% this year
- Code Chain New Continent Limited (CCNC) Stock Price Stood at $1.87 on Tuesday, October 20, What You Think?
Cyclerion Therapeutics Inc. (CYCN) share price plummeted -52.95% with the closing price of $3.35 on Wednesday. Cyclerion Therapeutics Inc. stock has an exchanging volume of 7.24 million shares, which is high, contrasted with its 3-months average volume of 266.47K shares. Its market capitalization has now reached to $114.30M.
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease on October 14, 2020 at Yahoo.
Cyclerion Therapeutics, Inc. (CYCN) declared top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator for the potential treatment of sickle cell disease (SCD). Olinciguat was generally well tolerated across all dose ranges. Results did not demonstrate adequate activity to support further internal clinical development. Cyclerion intends to complete its analysis of the study results and present or publish them in a future forum.
Cyclerion expects to be focused on the development of treatments for serious diseases of the central nervous system (CNS).
About STRONG-SCD Study
The STRONG-SCD study is a randomized, placebo-controlled, dose-ranging Phase 2 study of 70 participants designed to evaluate safety, tolerability, and pharmacokinetics of olinciguat, compared to placebo, as well as to explore effects on daily symptoms and biomarkers of disease activity when dosed over a 12-week treatment period.
CYCN Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, CYCN price has dropped by -51.38%. In the course of past three months sees the stock go down around -30.50%, while it has gain 8.77% over the past six months and 23.16% since the start of the year.
CYCN Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 749.0 million. For that equivalent quarter, Cyclerion Therapeutics Inc. posted -$0.7 earnings per share (EPS) which was above the consensus estimate of -$0.86 by $0.16, which represents to an expansion by 18.60%.
CYCN Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Cyclerion Therapeutics Inc. has seen its stock exchanging -62.61% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +6.01% above its three-month low. A more extensive look sees CYCN exchanging -77.32% beneath its 52-week high and 98.22% above from its 52-week low price.
CYCN Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 11.83%, while it has a month to month instability of 10.77%. The company has an ATR (Average True Range) of 0.89.